Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5084936 | 0.84 | CCNA2 (0.39) | CSNK2A2CSNK2BRPS6KB1AKT1 | |
| SCHEMBL3120919 | 0.84 | — | — | |
| SCHEMBL3117771 | 0.73 | PIM1 (0.31) | — | |
| SCHEMBL10726068 | 0.73 | PIM1 (0.31) | — | |
| SCHEMBL18208663 | 0.71 | KDM4E (0.40) | — | |
| SCHEMBL16516909 | 0.71 | HCAR2 (0.36) | HCAR2RPS6KB1AKT1 | |
| SCHEMBL1558502 | 0.71 | CCNA2 (0.38) | HCAR2CSNK2A2CSNK2A1CSNK2BRPS6KB1 | |
| Hydrochloric Acid SCHEMBL6052921 | 0.70 | CCNA2 (0.37) | HCAR2CSNK2A2CSNK2A1CSNK2BRPS6KB1 | |
| SCHEMBL14763163 | 0.69 | CDK9 (0.36) | — | |
| SCHEMBL2749122 | 0.69 | PIM1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009050554-A2 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. (US) | 2009-04-23 | — | — | WO | claimed |
| EP-1881985-A2 | ANHYDROUS CRYSTALLINE FORMS OF N-Ý1-(2-ETHOXYETHYL)-5-(N-ETHYL-N-METHYLAMINO)-7-(4-METHYLPYRIDIN-2-YL-AMINO)-1H-PYRAZOLO[4,3-D]PYRIMIDINE-3-CARBONYL¨METHANESULFONAMIDE | Pfizer, Inc. (US) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006120552-A2 | ANHYDROUS CRYSTALLINE FORMS OF N-[1-(2-ETHOXYETHYL)-5-(N-ETHYL-N-METHYLAMINO)-7-(4-METHYLPYRIDIN-2-yl-AMINO)-1H-PYRAZOLO[4,3-d]PYRIMIDINE-3-CARBONYL]METHANESULFONAMIDE | PFIZER INC. (US) | 2006-11-16 | — | — | WO | disclosed |